National Institute of Allergy and Infectious Disease

Isotechnika Pharma receives funding from NRC-IRAP

Thursday, June 27, 2013 02:00 PM

Biopharmaceutical Isotechnika Pharma has received additional funding from the Canadian National Research Council Industrial Research Assistance Program ("NRC-IRAP") for its Non-Immunosuppressive Cyclophilin Antagonist Molecules ("NICAMs") program. NRC-IRAP helped network the NICAM program with global partners and previously assisted Isotechnika in late-stage screening of several NICAM compounds, including evaluation of anti-hepatitis C virus ("HCV") activity.

More... »

FDA grants Soligenix Fast Track for OrbeShield for gastrointestinal acute radiation syndrome

Thursday, January 31, 2013 02:00 PM

Soligenix, a development-stage biopharmaceutical company, announced today that its OrbeShield (oral beclomethasone 17, 21-dipropionate or oral BDP) development program for the treatment of gastrointestinal acute radiation syndrome (GI ARS) has received Fast Track designation from the FDA.

More... »

Soligenix, IDRI to develop thermostabilized biodefense vaccines

Wednesday, June 27, 2012 09:44 AM

Soligenix, a development stage biopharmaceutical company, has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of Seattle, Wash., to develop select biodefense vaccines using IDRI's potent and safe synthetic adjuvants in conjunction with Soligenix's proprietary subunit proteins and thermostability platform, ThermoVax. 

More... »

NIH awards ImmuVen $1.68 million grant

Wednesday, May 2, 2012 11:54 AM

ImmuVen, a biotech based in Champaign, Ill., was awarded a phase II Small Business Innovation Research (SBIR) grant totaling $1.68 million from the National Institute for Allergy and Infectious Disease.

More... »

Soligenix, Harvard University partner to develop next generation anthrax vaccine

Thursday, December 15, 2011 04:15 PM

Soligenix, a development stage biopharmaceutical company, has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein. Initial development work will be covered pursuant to a previously issued $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant enabling development of thermo-stable ricin and anthrax vaccines.

More... »

Covance collaborates with Broad Institute, expands drug metabolism services

Thursday, August 4, 2011 11:54 AM

Covance said that its Seattle-based genomics laboratory will collaborate with the Broad Institute to create genomic resources for an important research model. Covance’s Next-Generation sequencing capabilities will be used to profile microRNA expression in various tissue samples from this model.

More... »